[[{“value”:”
Otsuka Pharmaceutical is acquiring Jnana Therapeutics, whose lead drug is a potential treatment for the rare metabolic disorder phenylketonuria (PKU). Jnana’s drug could provide an alternative to two FDA-approved PKU medicines from BioMarin Pharmaceutical.
The post Otsuka Commits $800M in M&A Deal Bringing a Phase 3-Ready Metabolic Disorder Drug appeared first on MedCity News.
“}]]
